Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda, a biotech startup, has secured $311 million in Series E funding, doubling its valuation to $2 billion. Led by Catalio Capital Management with participation from Iconiq, this funding will advance the company's mission to discover nature-derived drugs using AI. Enveda is currently progressing several AI-discovered drug candidates into human clinical trials, including treatments for severe skin conditions and maintaining weight loss after GLP-1s, aiming to bring these innovative therapies to patients.